Market cap
$8 Mln
Revenue (TTM)
$8 Mln
P/E Ratio
--
P/B Ratio
0.2
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 22.40 | 214.32 | 184.93 | -- | -- |
| EBIT | -- | -- | 48.43 | -1.16 | -- |
| Net Profit | -0.85 | 26.09 | 31.48 | -10.57 | -- |
| EPS | -- | -- | -- | -- | -- |
| Book Value | -- | -- | -- | -- | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-23 | Dec-22 |
| EBIT-Margin
| -18,017.80 | -- | -703.19 | -3,240.50 | -4,957.36 |
| Net Margin
| 217.84 | -- | -902.93 | -- | -5,356.78 |
| Return on equity
| -95.83 | -- | -276.36 | -118.82 | -66.95 |
| Return on Capital
| -67.73 | -- | -- | -61.86 | -58.81 |
| Return on Assets
| -54.21 | -- | -34.68 | -55.62 | -54.11 |
| Debt to Equity (x)
| -- | -- | 1.00 | 2.21 | 0.21 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Omega Therapeutics Inc (OMGA)
|
--
|
-61.86
|
-58.81
|
-82.53
|
78.52
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-276.36
Lower than Peers by 236.02
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Omega Therapeutics Inc (OMGA)
|
-276.36
|
-118.82
|
-66.95
|
-101.71
|
60.07
|
|
Peer Median
|
-40.33
|
--
|
--
|
--
|
--
|
ROA
-34.68
Lower than Peers by 3.44
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Omega Therapeutics Inc (OMGA)
|
-34.68
|
-55.62
|
-54.11
|
-52.91
|
-176.59
|
|
Peer Median
|
-31.24
|
--
|
--
|
--
|
--
|
EBIT Margin
-703.19
Lower than Peers by 620.59
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Omega Therapeutics Inc (OMGA)
|
-703.19
|
-3,240.50
|
-4,957.36
|
-45,855.56
|
--
|
|
Peer Median
|
-82.60
|
--
|
--
|
--
|
--
|
Net Margin
-902.93
Lower than Peers by 811.63
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Omega Therapeutics Inc (OMGA)
|
-902.93
|
-3,148.93
|
-5,356.78
|
5,792.46
|
--
|
|
Peer Median
|
-91.30
|
--
|
--
|
--
|
--
|
Cash Profit Margin
0.00
Lower than Peers by 0.00
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Omega Therapeutics Inc (OMGA)
|
0.00
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.00
|
--
|
--
|
--
|
--
|
Revenue Growth
184.93
Higher than Peers by 130.90
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Omega Therapeutics Inc (OMGA)
|
184.93
|
0.49
|
13.40
|
--
|
--
|
|
Peer Median
|
54.03
|
--
|
--
|
--
|
--
|
EBIT Growth
48.43
Higher than Peers by 49.45
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Omega Therapeutics Inc (OMGA)
|
48.43
|
2.44
|
-55.63
|
-130.52
|
-65.21
|
|
Peer Median
|
-1.02
|
--
|
--
|
--
|
--
|
Net Profit Growth
31.48
Higher than Peers by 39.02
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Omega Therapeutics Inc (OMGA)
|
31.48
|
5.07
|
-48.40
|
-129.02
|
-62.98
|
|
Peer Median
|
-7.53
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
1.00
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Omega Therapeutics Inc (OMGA)
|
1.00
|
2.21
|
0.21
|
0.10
|
-0.18
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
1.38
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Omega Therapeutics Inc (OMGA)
|
1.38
|
0.26
|
0.06
|
--
|
-0.05
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
1.61
Lower than Peers by 4.20
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Omega Therapeutics Inc (OMGA)
|
1.61
|
3.35
|
5.68
|
19.13
|
3.12
|
|
Peer Median
|
5.81
|
--
|
--
|
--
|
--
|
Quick Ratio
1.61
Lower than Peers by 4.08
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Omega Therapeutics Inc (OMGA)
|
1.61
|
3.34
|
3.80
|
19.16
|
--
|
|
Peer Median
|
5.70
|
--
|
--
|
--
|
--
|
Interest Coverage
-30.46
Lower than Peers by 28.38
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Omega Therapeutics Inc (OMGA)
|
-30.46
|
--
|
-462.91
|
-72.56
|
-36.87
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
6.00
Lower than Peers by 13.01
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Omega Therapeutics Inc (OMGA)
|
6.00
|
225.79
|
86.73
|
361.81
|
--
|
|
Peer Median
|
19.01
|
--
|
--
|
--
|
--
|
Asset Turnover
0.04
Lower than Peers by 0.03
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Omega Therapeutics Inc (OMGA)
|
0.04
|
0.02
|
0.01
|
0.00
|
--
|
|
Peer Median
|
0.06
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Omega Therapeutics Inc (OMGA)
|
--
|
518.48
|
204.30
|
905.52
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Omega Therapeutics Inc (OMGA)
|
--
|
114.93
|
1,438.73
|
-69.52
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Omega Therapeutics Inc (OMGA)
|
--
|
13.11
|
183.54
|
417.65
|
315.53
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Omega Therapeutics Inc (OMGA)
|
--
|
620.31
|
1,459.48
|
418.34
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Book Value
0.23
Lower than Peers by 5.09
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Omega Therapeutics Inc (OMGA)
|
0.23
|
--
|
--
|
--
|
--
|
|
Peer Median
|
5.33
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Omega Therapeutics Inc (OMGA)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
-2.12
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Omega Therapeutics Inc (OMGA)
|
-2.12
|
-0.59
|
1.05
|
3.18
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
8
Lower than Peers by 134
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Omega Therapeutics Inc (OMGA)
|
8
|
--
|
--
|
--
|
--
|
|
Peer Median
|
142
|
--
|
--
|
--
|
--
|